Cargando…
When is crossover desirable in cancer drug trials and when is it problematic?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961160/ https://www.ncbi.nlm.nih.gov/pubmed/29648572 http://dx.doi.org/10.1093/annonc/mdy116 |
| _version_ | 1783324686356054016 |
|---|---|
| author | Haslam, A Prasad, V |
| author_facet | Haslam, A Prasad, V |
| author_sort | Haslam, A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5961160 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59611602018-06-06 When is crossover desirable in cancer drug trials and when is it problematic? Haslam, A Prasad, V Ann Oncol Editorials Oxford University Press 2018-05 2018-04-10 /pmc/articles/PMC5961160/ /pubmed/29648572 http://dx.doi.org/10.1093/annonc/mdy116 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Editorials Haslam, A Prasad, V When is crossover desirable in cancer drug trials and when is it problematic? |
| title | When is crossover desirable in cancer drug trials and when is it problematic? |
| title_full | When is crossover desirable in cancer drug trials and when is it problematic? |
| title_fullStr | When is crossover desirable in cancer drug trials and when is it problematic? |
| title_full_unstemmed | When is crossover desirable in cancer drug trials and when is it problematic? |
| title_short | When is crossover desirable in cancer drug trials and when is it problematic? |
| title_sort | when is crossover desirable in cancer drug trials and when is it problematic? |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961160/ https://www.ncbi.nlm.nih.gov/pubmed/29648572 http://dx.doi.org/10.1093/annonc/mdy116 |
| work_keys_str_mv | AT haslama wheniscrossoverdesirableincancerdrugtrialsandwhenisitproblematic AT prasadv wheniscrossoverdesirableincancerdrugtrialsandwhenisitproblematic |